AZN vs. LLY, NVO, JNJ, MRK, ABBV, NVS, ABT, PFE, SNY, and VRTX
Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novartis (NVS), Abbott Laboratories (ABT), Pfizer (PFE), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "pharmaceutical preparations" industry.
AstraZeneca (NASDAQ:AZN) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.
In the previous week, Eli Lilly and Company had 43 more articles in the media than AstraZeneca. MarketBeat recorded 57 mentions for Eli Lilly and Company and 14 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.18 beat Eli Lilly and Company's score of 0.57 indicating that AstraZeneca is being referred to more favorably in the media.
AstraZeneca has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.
Eli Lilly and Company has a net margin of 17.08% compared to AstraZeneca's net margin of 13.30%. Eli Lilly and Company's return on equity of 56.98% beat AstraZeneca's return on equity.
AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 2.4%. Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.6%. AstraZeneca pays out 94.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and Company pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
AstraZeneca presently has a consensus target price of $88.00, suggesting a potential upside of 9.71%. Eli Lilly and Company has a consensus target price of $787.53, suggesting a potential downside of 9.05%. Given AstraZeneca's higher probable upside, analysts plainly believe AstraZeneca is more favorable than Eli Lilly and Company.
20.4% of AstraZeneca shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
AstraZeneca has higher revenue and earnings than Eli Lilly and Company. AstraZeneca is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Eli Lilly and Company received 1118 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 70.09% of users gave Eli Lilly and Company an outperform vote while only 58.95% of users gave AstraZeneca an outperform vote.
Summary
Eli Lilly and Company beats AstraZeneca on 13 of the 20 factors compared between the two stocks.
Get AstraZeneca News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AstraZeneca Competitors List
Related Companies and Tools
